IMA
ImageneBio Inc
Biotechnology
Market Cap$61M
5Y Perf.-96.8%
Build Your Comparison
Side-by-side financial analysisIMA
ARQT
SRZN
DERM
Try popular comparisons:
Stock Comparison
IMA vs ARQT vs SRZN vs DERM
Revenue, margins, valuation, and 5-year total return — side by side.
ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology
Market Cap$3.05B
5Y Perf.+47.1%
SRZN
Surrozen, Inc.
Biotechnology
Market Cap$175M
5Y Perf.-82.8%
DERM
Journey Medical Corporation
Drug Manufacturers - Specialty & Generic
Market Cap$174M
5Y Perf.-19.8%
IMA vs ARQT vs SRZN vs DERM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  IMA |  ARQT |  SRZN |  DERM |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $61M | $3.05B | $175M | $174M |
| Revenue (TTM) | $0.00 | $416M | $7M | $65M |
| Net Income (TTM) | $-45M | $-2M | $-343M | $-10M |
| Gross Margin | -29.1% | 90.9% | 99.1% | 60.4% |
| Operating Margin | -60.6% | 0.8% | -5.7% | -9.8% |
| Forward P/E | — | 122.5x | — | 97.5x |
| Total Debt | $10M | $6M | $7M | $119K |
| Cash & Equiv. | $35M | $43M | $89M | $24M |
IMA vs ARQT vs SRZN vs DERM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IMA
ARQT
SRZN
DERM
| Stock | Nov 21 | Jun 26 | Return |
|---|---|---|---|
| ImageneBio Inc (IMA) | 100 | 3.2 | -96.8% |
| Arcutis Biotherapeu… (ARQT) | 100 | 147.1 | +47.1% |
| Surrozen, Inc. (SRZN) | 100 | 17.2 | -82.8% |
| Journey Medical Cor… (DERM) | 100 | 80.2 | -19.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IMA vs ARQT vs SRZN vs DERM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ARQT leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. ImageneBio Inc is the stronger pick specifically for capital preservation and lower volatility. SRZN and DERM also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ARQT emerged as the overall leader. Track its performance:
IMA
ImageneBio Inc
The Income Pick
IMA is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.83
- Lower volatility, beta 0.83, Low D/E 7.5%, current ratio 12.49x
- Beta 0.83, current ratio 12.49x
- Beta 0.83 vs DERM's 1.98
Best for: income & stability and sleep-well-at-night
ARQT
Arcutis Biotherapeutics, Inc.
The Growth Play
ARQT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 91.3%, EPS growth 88.8%, 3Y rev CAGR 367.3%
- 11.8% 10Y total return vs DERM's -33.3%
- 91.3% revenue growth vs IMA's -77.1%
- -0.6% margin vs IMA's -56.7%
Best for: growth exposure and long-term compounding
SRZN
Surrozen, Inc.
The Momentum Pick
SRZN is the clearest fit if your priority is momentum.
- +148.8% vs IMA's -67.0%
Best for: momentum
DERM
Journey Medical Corporation
The Value Play
DERM is the clearest fit if your priority is value.
- Better valuation composite
Best for: value
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ARQT | 91.3% revenue growth vs IMA's -77.1% |
| Value |  DERM | Better valuation composite |
| Quality / Margins | ARQT | -0.6% margin vs IMA's -56.7% |
| Stability / Safety |  IMA | Beta 0.83 vs DERM's 1.98 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  SRZN | +148.8% vs IMA's -67.0% |
| Efficiency (ROA) | ARQT | -0.6% ROA vs SRZN's -329.2% |
IMA vs ARQT vs SRZN vs DERM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
FY 2025
FY 2025
IMA vs ARQT vs SRZN vs DERM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARQTLAGGINGSRZN
Who Leads Where
ARQT leads in 2 of 6 categories
DERM leads 1 • IMA leads 0 • SRZN leads 0 • 2 tied
Explore the data ↓SRZNSurrozen, Inc.
0leads
IMAImageneBio Inc
0leads
DERMJourney Medical Corpo…
1leads
ARQTArcutis Biotherapeuti…
2leads
6 Total Categories
CATEGORYLEADERvs DERMvs IMAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARQT3/6
Valuation MetricsMultiples, price ratios, and targets
DERM2/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARQT6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARQT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARQT and IMA operate at a comparable scale, with $416M and $0 in trailing revenue. ARQT is the more profitable business, keeping -0.6% of every revenue dollar as net income compared to IMA's -56.7%. On growth, SRZN holds the edge at +4.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | IMAImageneBio Inc | ARQTArcutis Biotherap… | SRZNSurrozen, Inc. | DERMJourney Medical C… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $416M | $7M | $65M |
| EBITDAEarnings before interest/tax | -$53M | $6M | -$43M | -$2M |
| Net IncomeAfter-tax profit | -$45M | -$2M | -$343M | -$10M |
| Free Cash FlowCash after capex | -$52M | $27M | -$34M | -$7M |
| Gross MarginGross profit ÷ Revenue | -29.1% | +90.9% | +99.1% | +60.4% |
| Operating MarginEBIT ÷ Revenue | -60.6% | +0.8% | -5.7% | -9.8% |
| Net MarginNet income ÷ Revenue | -56.7% | -0.6% | -45.7% | -14.8% |
| FCF MarginFCF ÷ Revenue | -59.8% | +6.5% | -4.5% | -10.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +60.1% | +4.1% | +21.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.3% | +55.0% | -56.8% | +55.6% |
ARQT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
DERM leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | IMAImageneBio Inc | ARQTArcutis Biotherap… | SRZNSurrozen, Inc. | DERMJourney Medical C… |
|---|---|---|---|---|
| Market CapShares × price | $61M | $3.0B | $175M | $174M |
| Enterprise ValueMkt cap + debt − cash | $36M | $3.0B | $92M | $151M |
| Trailing P/EPrice ÷ TTM EPS | -0.50x | -187.54x | -0.72x | -13.49x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 122.45x | — | 97.54x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 76.54x | 8.11x | 50.30x | 2.82x |
| Price / BookPrice ÷ Book value/share | 0.20x | 16.37x | — | 4.88x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
DERM leads this category, winning 2 of 4 comparable metrics.
Profitability & Efficiency
ARQT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ARQT delivers a -1.4% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-36 for DERM. DERM carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to IMA's 0.08x. On the Piotroski fundamental quality scale (0–9), ARQT scores 4/9 vs IMA's 2/9, reflecting mixed financial health.
| Metric | IMAImageneBio Inc | ARQTArcutis Biotherap… | SRZNSurrozen, Inc. | DERMJourney Medical C… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -35.2% | -1.4% | — | -35.6% |
| ROA (TTM)Return on assets | -31.3% | -0.6% | -3.3% | -10.9% |
| ROICReturn on invested capital | -35.9% | -5.2% | — | -36.8% |
| ROCEReturn on capital employed | -35.6% | -4.3% | -64.8% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.08x | 0.03x | — | 0.00x |
| Net DebtTotal debt minus cash | -$25M | -$37M | -$83M | -$24M |
| Cash & Equiv.Liquid assets | $35M | $43M | $89M | $24M |
| Total DebtShort + long-term debt | $10M | $6M | $7M | $119,000 |
| Interest CoverageEBIT ÷ Interest expense | -560.22x | 2.08x | — | -1.67x |
ARQT leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ARQT and SRZN and DERM each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARQT five years ago would be worth $8,384 today (with dividends reinvested), compared to $330 for IMA. Over the past 12 months, SRZN leads with a +148.8% total return vs IMA's -67.0%. The 3-year compound annual growth rate (CAGR) favors DERM at 56.0% vs IMA's -59.4% — a key indicator of consistent wealth creation.
| Metric | IMAImageneBio Inc | ARQTArcutis Biotherap… | SRZNSurrozen, Inc. | DERMJourney Medical C… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -19.7% | -15.9% | +8.5% | -14.9% |
| 1-Year ReturnPast 12 months | -67.0% | +80.6% | +148.8% | -9.0% |
| 3-Year ReturnCumulative with dividends | -93.3% | +138.8% | +149.5% | +279.6% |
| 5-Year ReturnCumulative with dividends | -96.7% | -16.2% | -84.2% | -33.3% |
| 10-Year ReturnCumulative with dividends | -98.6% | +11.8% | -84.6% | -33.3% |
| CAGR (3Y)Annualised 3-year return | -59.4% | +33.7% | +35.6% | +56.0% |
Evenly matched — ARQT and SRZN and DERM each lead in 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMA and ARQT each lead in 1 of 2 comparable metrics.
Risk & Volatility
IMA is the less volatile stock with a 0.83 beta — it tends to amplify market swings less than DERM's 1.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARQT currently trades 76.7% from its 52-week high vs IMA's 30.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMAImageneBio Inc | ARQTArcutis Biotherap… | SRZNSurrozen, Inc. | DERMJourney Medical C… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.83x | 1.45x | 1.25x | 1.98x |
| 52-Week HighHighest price in past year | $18.00 | $31.77 | $35.00 | $9.55 |
| 52-Week LowLowest price in past year | $1.36 | $12.72 | $8.00 | $4.31 |
| % of 52W HighCurrent price vs 52-week peak | +30.2% | +76.7% | +66.8% | +66.4% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 66.4 | 41.7 | 58.3 |
| Avg Volume (50D)Average daily shares traded | 432K | 1.5M | 111K | 204K |
Evenly matched — IMA and ARQT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ARQT as "Buy", SRZN as "Buy", DERM as "Buy". Consensus price targets imply 85.3% upside for DERM (target: $12) vs 39.5% for ARQT (target: $34).
| Metric | IMAImageneBio Inc | ARQTArcutis Biotherap… | SRZNSurrozen, Inc. | DERMJourney Medical C… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $34.00 | $42.00 | $11.75 |
| # AnalystsCovering analysts | — | 12 | 6 | 3 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARQT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DERM leads in 1 (Valuation Metrics). 2 tied.
Best OverallArcutis Biotherapeutics, In… (ARQT)Leads 2 of 6 categories
Loading custom metrics...
IMA vs ARQT vs SRZN vs DERM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is IMA or ARQT or SRZN or DERM a better buy right now?
For growth investors, Arcutis Biotherapeutics, Inc.
(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -77. 1% for ImageneBio Inc (IMA). Analysts rate Arcutis Biotherapeutics, Inc. (ARQT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMA or ARQT or SRZN or DERM?
Over the past 5 years, Arcutis Biotherapeutics, Inc.
(ARQT) delivered a total return of -16. 2%, compared to -96. 7% for ImageneBio Inc (IMA). Over 10 years, the gap is even starker: ARQT returned +11. 8% versus IMA's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMA or ARQT or SRZN or DERM?
By beta (market sensitivity over 5 years), ImageneBio Inc (IMA) is the lower-risk stock at 0.
83β versus Journey Medical Corporation's 1. 98β — meaning DERM is approximately 138% more volatile than IMA relative to the S&P 500. On balance sheet safety, Journey Medical Corporation (DERM) carries a lower debt/equity ratio of 0% versus 8% for ImageneBio Inc — giving it more financial flexibility in a downturn.
04Which is growing faster — IMA or ARQT or SRZN or DERM?
By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.
(ARQT) is pulling ahead at 91. 3% versus -77. 1% for ImageneBio Inc (IMA). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -954. 9% for ImageneBio Inc. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IMA or ARQT or SRZN or DERM?
Arcutis Biotherapeutics, Inc.
(ARQT) is the more profitable company, earning -4. 3% net margin versus -69. 6% for Surrozen, Inc. — meaning it keeps -4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARQT leads at -3. 3% versus -60. 6% for IMA. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is IMA or ARQT or SRZN or DERM more undervalued right now?
On forward earnings alone, Journey Medical Corporation (DERM) trades at 97.
5x forward P/E versus 122. 5x for Arcutis Biotherapeutics, Inc. — 24. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 85. 3% to $11. 75.
07Which pays a better dividend — IMA or ARQT or SRZN or DERM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is IMA or ARQT or SRZN or DERM better for a retirement portfolio?
For long-horizon retirement investors, ImageneBio Inc (IMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
83)). Journey Medical Corporation (DERM) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMA: -98. 6%, DERM: -33. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between IMA and ARQT and SRZN and DERM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IMA is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; SRZN is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.